Guardant Health, Inc. announced results from the LIBERATE study, published in ESMO Open, demonstrating the clinical validity and high performance of Guardant Reveal. This minimal residual disease (MRD) blood test predicts recurrence in patients with early-stage breast cancer.
The study retrospectively analyzed 290 blood samples from 95 patients with early-stage ER+/HER2- or triple-negative breast cancer. Key findings include a 99% specificity for recurrence-free survival and a 70% sensitivity for metastatic recurrence in patients with residual disease after neoadjuvant chemotherapy.
Craig Eagle, M.D., Guardant Health chief medical officer, emphasized that the study underscores Guardant Reveal's robust prognostic value and high specificity in identifying breast cancer patients at elevated risk of recurrence without needing a tissue sample. These findings reinforce the test's critical role in clinical decision-making and potential to transform surveillance strategies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.